Vic Neufeld, Chief Executive Officer of Aphria, said:
“As the first licensed producer to partner with Shoppers Drug Mart, we are pleased to have reached this milestone.
This marks another important step for medical cannabis in Canada providing improved access for patients in need across the country.
“The potential cannabis has for medical purposes is still largely untapped and Aphria remains committed to investing in developing new and innovative products that address unmet patient needs. For example, we will start to produce a thin, quick-dissolve strip that may provide an effective and accurate dose delivery,” added Neufeld.
The Company had previously announced a supply agreement with Shoppers Drug Mart.
Aphria is a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.
For more information, visit: aphria.ca.
SOURCE Aphria Inc.
Featured image courtesy of Technical420.